Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

24.33 -1.17 (-4.59%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

58 Biggest Movers From Yesterday ↗

December 17, 2021

Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Down 2.5%; Calliditas Therapeutics Shares Spike Higher ↗

December 16, 2021

Toward the end of trading Thursday, the Dow traded up 0.05% to 35,946.32 while the NASDAQ fell 2.5% to 15,179.38. The S&P also fell, dropping 0.80% to 4,672.38. The U.S. has...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

Promising Developments in Breast Cancer Treatments Ahead in 2022

January 12, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against...

Via FinancialNewsMedia

Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease ↗

December 20, 2021

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in adult patients who are anti-...

Via Benzinga

Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board ↗

December 18, 2021

BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 16, 2021

Gainers Calliditas Therapeutics (NASDAQ:CALT...

Via Benzinga

31 Stocks Moving In Thursday's Mid-Day Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce...

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Zai Lab's Nuzyra Approved In China For Bacterial Infections ↗

December 16, 2021

The China National Medical Products Administration (NMPA) has approved Zai Lab Limited's (NASDAQ: ZLAB) Nuzyra (omadacycline), a novel antibiotic with both oral...

Via Benzinga

46 Biggest Movers From Yesterday ↗

December 16, 2021

Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 15, 2021

Gainers Biofrontera (NASDAQ:

Via Benzinga

36 Stocks Moving In Wednesday's Mid-Day Session ↗

December 15, 2021

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates ↗

December 15, 2021

Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million ↗

November 13, 2021

Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.

Via Talk Markets

Why Karuna Therapeutics Stock Tumbled This Week ↗

November 12, 2021

Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.

Via The Motley Fool

Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates ↗

November 09, 2021

Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...

Via Benzinga

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

November 09, 2021

From PureTech Health plc

Via Business Wire

Earnings Scheduled For November 9, 2021 ↗

November 09, 2021

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings...

Via Benzinga

Week In Review: China's Hansoh Signs Two siRNA Deals Worth $1.7 Billion ↗

October 23, 2021

Hansoh announced a $1.3 billion deal to develop three siRNA candidates from London's Silence Therapeutics. In the past week, Hansoh also revealed a $456 million deal with Korea's OliX Pharma for China...

Via Talk Markets

Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial ↗

October 21, 2021

Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque...

Via Benzinga

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

October 21, 2021

From Crescendo Biologics Ltd

Via Business Wire

Week In Review: Hansoh Signs $456 Million Deal For siRNA Products ↗

October 16, 2021

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 ↗

October 12, 2021

Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...

Via Benzinga

Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products ↗

October 10, 2021

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed...

Via Talk Markets

Topics Initial Public Offering

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗

September 19, 2021

Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.